


RESOURCES

Home

China Compliance: Systems and Standards at a Glance



China is quickly ramping up its regulatory infrastructure and setting deadlines—and you need to be ready. This visual guide provides an overview of the key features of China’s Drug Administration Law so you can begin your 2021 serialization and compliance planning now.

Topics include:

- The latest regulatory timeline, including the December deadline for 4 medicine classes
- China’s 3-tier reporting system and the importance of “horizontal integration” with downstream partners
- Master data and traceability data requirements
- Key differences between China EDMC and GS1-compatible identifiers

China Compliance: Systems and Standards at a Glance




China's Drug Administration Law (DAL) establishes a drug traceability system to ensure that all information generated in drug research, manufacturing, distribution, and usage is true, accurate, and traceable.

This visual guide provides an overview of the key requirements of the law based on the latest available information. [Contact TraceLink](#) to learn more about TraceLink's China Special Interest Group and stay up to date on the China regulations.

▶ REGULATORY TIMELINE

It is expected that China's regulatory authority, NMPA (National Medical Products Administration) will continue to publish additional intermediate deadlines between December 2020 and when reporting goes into effect for all medicines.



▶ WHO IS AFFECTED?



Importers



Marketing Authorization Holders (MAHs) / Manufacturers



Drug Distributors

[China Pharmaceuticals](#)

[China](#)

[Contact Us](#)

[Contact Us](#)

[Contact Us](#)